In the same two-year period, he has sponsored nine and co-sponsored 35 health-related bills in the House. His stock trades included Amgen Inc., Bristol Meyers Squibb Co., Eli Lilly & Co., Pfizer Inc. and Aetna Inc.
His largest single stock buy was an August 2016 purchase of between $50,000 and $100,000 of an Australian biomedical firm, Innate Immunotherapeutics Inc., whose largest shareholder is a GOP congressman on the Trump transition team, according to the filings, which list price ranges. The stock has since doubled in price.
Price spokesman Phil Blando told the Journal that the Roswell Republican has “complied fully with all applicable laws and ethics rules governing his personal finances,” and that he would comply with the law if confirmed. Another Price aide declined further comment.
The trading is sure to be invoked during his Senate confirmation hearings next year. A 2012 law bans members and employees of Congress from using "nonpublic information" for their own financial benefit.